CD274 and neoplasm: Furthermore, the absence of biomarker stratification—such as PD-L1 expression, tumor mutational burden (TMB), or tumor-infiltrating lymphocytes (TILs)—restricts the ability to identify subgroups that may derive differential benefit from immunotherapy.